Steve Chinowsky, Darryl Steensma, Sara Patel, Kevin Reyes, Patrick English, Kirt Switzer, Jake Meninga, Heather Deixler
January 24, 2026
Latham & Watkins Advises Gossamer Bio in Global Collaboration With Chiesi
1 min
AI-made summary
- Gossamer Bio, Inc
- and Chiesi Farmaceutici S.p.A have entered into a global collaboration and license agreement to develop and commercialize seralutinib for the treatment of pulmonary hypertension
- Latham & Watkins LLP represented Gossamer Bio in the transaction, with legal advice provided by a team covering healthcare, life sciences, corporate, antitrust, tax, and data privacy matters across multiple offices including San Diego, London, Washington, D.C., and San Francisco.
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, and Chiesi Farmaceutici S.p.A international, research-focused biopharmaceutical group, have announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib. Latham & Watkins LLP represented Gossamer Bio in the transaction with a healthcare and life sciences team led by San Diego partner Steve Chinowsky, and San Diego counsel Darryl Steensma, with London associate Sara Patel. Advice was also provided on corporate matters by San Diego partner Kevin Reyes; on antitrust matters by Washington, D.C. partner Patrick English; on tax matters by San Francisco partner Kirt Switzer, with associate Jake Meninga; and on data privacy matters by San Francisco partner Heather Deixler.~~
Article Author
Steve Chinowsky, Darryl Steensma, Sara Patel, Kevin Reyes, Patrick English, Kirt Switzer, Jake Meninga, Heather Deixler
The Sponsor
